🧬 POTOMAC: Exploratory papillary-only high-risk NMIBC analysis
https://oncodaily.com/oncolibrary/immune-oncology/potomac-trial-esmo
Durvalumab + BCG vs BCG alone:
📊 DFS HR 0.56
⏳ Cystectomy-free survival HR 0.59
⚠️ Grade 3/4 TRAEs: 23% vs 3%
Post hoc findings; cystectomy-free survival includes death.
#ESMO2026 #OncoDaily #POTOMAC
34 浏览 · 2 赞 · 0 转发 · 0 回复
Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT
https://esmocongress.esmo.orgRapid oral 1: Genitourinary tumours, renal and urothelial
https://esmocongress.esmo.orgHealth-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY
https://esmocongress.esmo.orgRapid oral 1: Genitourinary tumours, renal and urothelial
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgEnfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.org来源：OncoDaily IO · x.com